Hims & Hers’ offices are located in one of those glass buildings in San Francisco, where startup workers are constantly switching between laptops and whiteboards late in the afternoon. A delivery man unloads packages by the door, and scooters line the sidewalk outside the lobby. Nothing about the structure indicates that it is home to a business that is currently valued at over $5 billion.
However, the ticker HIMS has unexpectedly emerged as one of the most watched healthcare stocks on Wall Street.
CategoryDetailsCompany NameHims & Hers Health, Inc.Stock TickerHIMSExchangeNYSEIndustryTelehealth / Digital HealthcareMarket Capitalization~$5.3 BillionCurrent Stock Price~$22–$2352-Week Range$13.74 – $70.43Price/Earnings Ratio~43Active Subscribers~2.5 million usersCore ProductsTelehealth prescriptions, mental health care, weight-loss treatmentsHeadquartersSan Francisco, CaliforniaOfficial Websitehttps://www.hims.com
In a single trading session, shares of Hims & Hers recently increased by over 40%. The move followed an announcement that surprised even seasoned investors: the company had reached an agreement with pharmaceutical giant Novo Nordisk, ending a legal dispute and opening the door for Hims to sell the blockbuster weight-loss drugs Ozempic and Wegovy through its telehealth platform.
There was a feeling that the market was reevaluating the entire business model as the chart spiked that day.
Hims & Hers occupied a peculiar area of healthcare for many years. It began as a direct-to-consumer telehealth platform offering treatments for mental health issues, acne, erectile dysfunction, and hair loss. The pitch was straightforward: order medication online instead of making the awkward trip to the doctor’s office.
The ease of remote consultations and covert delivery boxes to their front doors attracted millions of customers. In secret, what appeared to be a niche startup grew into a sizable subscription company. The boom of weight-loss drugs followed.
Globally, demand for GLP-1 drugs like Ozempic and Wegovy surged. Originally created to treat diabetes, these medications gained notoriety for their dramatic effects on weight loss. Prescription demand increased so rapidly in the US alone that shortages emerged.
Seeing a chance, Hims started selling compounded semaglutide through affiliated pharmacies. The strategy brought rapid growth — and controversy.
Earlier this year, Wegovy’s Danish pharmaceutical manufacturer, Novo Nordisk, filed a patent lawsuit against Hims. The main focus of the accusation was what Novo called “copycat versions of its drug circulating through compounding pharmacies.”
The disagreement appeared to pose a threat to Hims’ business strategy for a while. Then an unforeseen event occurred.
Rather than pursuing legal action, the companies came to an agreement. Novo Nordisk consented to let Hims use the platform to directly distribute its FDA-approved drugs. Hims agreed to cease marketing compounded GLP-1 medications in return.
It’s possible that the market now sees Hims more as a distribution channel for major pharmaceutical companies than as a disruptive outsider. That difference is important. Companies that sell approved medications are typically viewed more favorably by healthcare regulators than those that sell compounded alternatives. Nevertheless, there is hesitation along with the enthusiasm.
The stock is still well below its peak of about $70 from the previous year, despite the recent surge. The decrease was a reflection of worries about competition, regulations, and the long-term viability of telehealth expansion following the pandemic. Additionally, Hims is an exceptionally erratic stock.
The shares have moved more than five percent numerous times in the last year alone. On some days, the fluctuations feel more like trading a tech startup than investing in healthcare. Sometimes, investors who chase momentum find out how easily that momentum can turn around.
However, the overall trend in digital healthcare appears to be indisputable.
Silently, telehealth platforms have evolved into entry points into the medical system. These days, patients use apps to make appointments, get prescriptions online, and use video calls to communicate with doctors. This process seems natural, especially to younger consumers. The true question might be whether businesses like Hims can grow quickly without losing their credibility.
Shipping vitamins or shampoo entails different obligations than selling pharmaceutical treatments. There is more stringent regulation. There is more liability. Partnerships with drugmakers must be carefully structured. As this change takes place, it seems like Hims is moving into a new phase of its development.
The business started out as a startup offering smartphone-based, convenient healthcare. It currently occupies a position halfway between a pharmaceutical distributor and a tech platform. This hybrid identity has the potential to become complex or powerful.
Employees in the San Francisco office are still working behind glass walls, developing software, forming alliances, and growing telehealth services. The stock chart outside conveys a more sentimental narrative.
One day, regulatory news or concerns about inflation cause HIMS to plummet. On a different day, it increases by forty percent due to the dissolution of a lawsuit and the formation of a new alliance.
Investors appear to think the business could still develop into something much bigger. However, the future is still uncertain.
It seems like Hims & Hers is still figuring out what kind of business it wants to become in the end—a startup disruptor, a healthcare platform, or something in between—based on the volatility.
Post navigation